Maternal Serum Adropin in Placenta Accreta Spectrum

NCT07421180 | Completed DMC

• 1 other identifier: 79/25.07.2024
• Study Type: observational
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion. Methods: This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.

Conditions

Placenta Accreta Spectrum; Placenta Previa

Keywords

Placenta accreta spectrum; Placenta previa; Adropin; Endothelial dysfunction; Biomarker

Outcome Measures

Primary Outcomes (1)

• Blood serum Adropin levels

  The aim of the present study was to evaluate maternal serum adropin levels in pregnancies complicated by placenta previa and placenta accreta spectrum and compare to healthy controls.

  From 15.04.2024 to 01.04.2025

Study Arms (2)

Study group (Diagnosed with Plasenta Previa and/or Placenta accreta spectrum)

Pregnant women aged 18-45 years viable third-trimester pregnancies diagnosed with placenta previa and/or PAS (Placenta accreta spectrum)

control group

healthy pregnant women in the third trimester with similar demographic characteristics

Eligibility Criteria

• Age: 18 Years - 45 Years
• Gender Eligibility Details: Pregnant women in third trimester
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Pregnant women aged 18-45 years in the reproductive period with singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS were included in the study. The control group consisted of healthy pregnant women in the third trimester with similar demographic characteristics who underwent elective cesarean delivery and had no obstetric or medical comorbidities.

You may qualify if:

• Pregnant women aged 18-45 years in the reproductive period
• Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS

You may not qualify if:

• Uterine anomalies,
• Chronic systemic diseases,
• Multiple pregnancies,
• Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.

Sponsors & Collaborators

• Adana City Training and Research Hospital: lead

Study Sites (1)

University of Heath and Science Adana City Hospital

Adana, Yuregir, 01100, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum human adropin concentrations were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Elabscience, catalog no. E-EL-H5307) according to the manufacturer's instructions. After incubation at room temperature, absorbance was measured at 450 nm using a microplate reader (BioTek ELx800) and an automated strip washer (BioTek ELx50). Adropin concentrations were calculated by comparing sample optical densities with a reference range of 12.5-800 pg/mL.

MeSH Terms

Conditions

Placenta Accreta; Placenta Previa

Condition Hierarchy (Ancestors)

Obstetric Labor Complications; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Placenta Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor Gulsum Uysal

Study Record Dates

• First Submitted: February 12, 2026
• First Posted: February 19, 2026
• Study Start: May 15, 2024
• Primary Completion: April 1, 2025
• Study Completion: April 1, 2025
• Last Updated: February 20, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)